* Lung function assessed by Peak Expiratory Flow (PEF)
* Nasal airflow assessed by Peak Nasal Inspiratory Flow (PNIF)
* Serum levels of allergen-specific IgE to Can f 1, Can f 2, Can f 3, Can f 4, Can f 5, and Can f 6
* Symptom severity assessed using a Visual Analogue Scale (VAS)
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject has provided written informed consent to participate in the study.
Age 18-50 years.
Moderate-to-severe allergic symptoms upon exposure to dogs.
Dog allergy confirmed by positive specific IgE.
Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).
Female subjects of childbearing potential must use adequate contraception.
A negative pregnancy test must be obtained prior to enrolment.
You may not be if
Pregnancy or breastfeeding.
Autoimmune or connective tissue disease.
Cardiovascular disease.
Hepatic disease.
Renal disease.
Malignancy.
Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).
Chronic obstructive or restrictive lung disease.
Treatment with medications that may interfere with the immune response.
Previous immunotherapy or chemotherapy.
Significant chronic disease.
Major metabolic disease.
Alcohol or substance abuse.
Mental or cognitive incapacity that may impair compliance with study procedures.
Known or suspected hypersensitivity to the study product.
Suspected or confirmed bacterial infection.
Clinically relevant allergy to house dust mite.
Current dog ownership.
Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.
Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.
Clareo Health | Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
